Zoetis (ZTS) Given Daily News Sentiment Rating of 0.13
Headlines about Zoetis (NYSE:ZTS) have been trending somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Zoetis earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.9952595941995 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern’s analysis:
- $0.63 EPS Expected for Zoetis Inc. (ZTS) This Quarter (americanbankingnews.com)
- Interesting ZTS Put And Call Options For October 27th (stockoptionschannel.com)
- Zoetis Shows Market Leadership With Jump To 82 RS Rating (finance.yahoo.com)
- Zoetis’ (ZTS) Buy Rating Reaffirmed at Cantor Fitzgerald (americanbankingnews.com)
- Zoetis Announces Pricing of $1.25 Billion of Senior Notes – Business Wire (press release) (businesswire.com)
Zoetis (NYSE:ZTS) traded down 0.23% on Friday, reaching $64.70. 2,608,157 shares of the company’s stock traded hands. The stock has a market cap of $31.65 billion, a price-to-earnings ratio of 36.57 and a beta of 1.02. The stock has a 50 day moving average price of $61.87 and a 200 day moving average price of $58.97. Zoetis has a 12-month low of $46.86 and a 12-month high of $65.12.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, meeting the consensus estimate of $0.53. The business had revenue of $1.27 billion for the quarter, compared to the consensus estimate of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.49 EPS. Analysts forecast that Zoetis will post $2.34 EPS for the current year.
Several equities research analysts recently issued reports on ZTS shares. Cantor Fitzgerald set a $75.00 target price on shares of Zoetis and gave the stock a “buy” rating in a report on Monday, August 14th. Stifel Nicolaus restated a “buy” rating and issued a $65.00 target price on shares of Zoetis in a report on Friday, September 1st. Argus restated a “buy” rating and issued a $69.00 target price (up previously from $60.00) on shares of Zoetis in a report on Tuesday, May 30th. CL King started coverage on shares of Zoetis in a report on Friday, May 26th. They issued a “buy” rating and a $71.00 target price on the stock. Finally, Deutsche Bank AG restated a “buy” rating and issued a $65.00 target price (up previously from $62.00) on shares of Zoetis in a report on Monday, July 17th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $65.44.
COPYRIGHT VIOLATION WARNING: This story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/10/zoetis-zts-given-daily-news-sentiment-rating-of-0-13.html.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.